requirement Panacea Biotech Limitedn – Regulatory Affairs.

  Requirement Panacea Biotech Limitedn – Regulatory Affairs.

Age : 38-45 yrs

Develop a robust mechanism of gathering inputs from the customers required for error free dossier compilation & submission.

Developing product related regulatory objectives & timelines for critical activities

Online query response

Post Name :In-charge – Regulatory Affairs

Qualification:Any Graduate – Any Specialization,M.Pharma – Pharmacy,Doctorate: Ph.D with 12-20 years of experience.

Location : India-Mumbai

Age Limit: 38-45 years

Nationality :Indian

Salary: 16-25 L P.A

Contact:

nitinmalhotra@panaceabiotec.com

Website:https://www.panacea-biotec.com/

Telephone:011-41679023

Openings:01

Selection Process : Candidates should be selected as based on candidate performance in interview.

Opening Date: 12-10-2018

About Panacea Biotech Limited

Panacea Biotech is an innovative healthcare company based on India's most progressive research and development, manufacture and marketing of pharmaceuticals, biopharmaceuticals, vaccines and natural / indigenous products. Our guidance in the past, current and future home and global spheres is done through the view of "Innovative in Life Support".

Panesia Drugs Pvt. Ltd. was established in 1984, new and innovative medicines to make the public dream of a cheap India dream and to be listed as Panacea Biotech Limited in 1995.

Panacea Biotech has shown the time for expanding new products from every product of our business to market customers, from the product to regulatory approval and thereby providing the basis for translating our vision to become the world's largest, largest, and most appreciable biotechnology company. Until 2020

Unprecedented research and development efforts have always been a major strength for Penéca Biotech. New research institute (NCE), new biological organization (NBE) new drug distribution system (NDS) based pharmaceutical formulations, Novell Peptides and human monoclonal antibodies and vaccine are developed. The company has developed four prestigious, ultra-modern, advanced R & D centers in various places, there are internal capabilities for continuous research, more than 300 professional and skilled scientists in various aspects of the search.

Focus research efforts have been approved for the patent purchase of Panissia Biotech world products, which are valid in 68 countries. On March 31, 2011, the company filed 1,400 patent applications in various parts of the world including India. Of these, 382 patents have been approved and are in different stages of examination or publication by other patent officers. Some of these countries are USA, UK, France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea and China

Our aspiration is supported by our globally recognized USFDA accredited manufacturing facility, where 4 "State of the Art" R & D Centers are supported in Baddi.

The company has state-of-the-art modern state-of-the-art manufacturing facilities for making production tablets, capsules (including soft gelatin), stool (transgen formulation), herbal formulations and vaccine in Baddi (Himachal Pradesh), Lalru (Punjab) and Delhi. . WHO CGMP is USFDA, UKMHRA, Saudi FDA, Anvisia etc. Similar to other regulatory bodies.

Product portfolio includes highly innovative medicinal products in specific therapeutic areas like Pension Management, Diabetes and Cardiovascular Management, Oncology, Renal Disease Management, Osteoporosis Management, Anti-Tuberculular, Gastro-Intensive Care Products and Vaccines. Our current business is composed of our leadership departments in India such as transplantation, nephrology, diabetes and pains with certain products based on patented drug medicine systems.

Our first nanotechnology-based product was 'Packalal' (Protein Bound Particle Paxetexel) launched in 2011; Produced by Cellegen USA, it was the world's first generic for Abroxen. In addition to strengthening our presence in the above departments; We are planning major in gastrointestinal, osteoporosis, cardiovascular and more important oncology.

Panacea Biotech is the largest vaccine manufacturing company in India, and the United Nations Health Agency has given full recognition to the polio eradication initiative by providing millions of WHO pre-qualified polio vaccines. To complete the entire range of Oral Polio Vaccine (TOPV, MOPV1, MOPV3 and BOPV) respectively. Pendeska Biotech has started the next generation of passive polio vaccine (EIPV) in association with the Netherlands Vaccine Institute (NVI). The vaccine has now been widely used in India for more than 3 years and has registered in Bangladesh. The IPV is also at an advanced level of registration in 10 countries, which aims to target more than 30 countries in some years and has been prepared for WHO's eligibility soon.

Panacea Biotech is the first company in which the entire liquid Pentavalent vaccine (DTWP + Hep B + Hib) Easy Five has been developed in 2005. Easy Five is using WHO fluid used in more than 25 countries worldwide. The vaccine portfolio includes annexe-HB (Hepatitis B vaccine), Enivac-HB Suffice, Ecovac-4 (DTWP + Hep B), EasyFor (DTWP + Hib), which are also pre-qualified. There are vaccines in the offing- anthrax, dengue, Japanese encephalitis and many others. The strong innovative vaccine pipeline is in the future, which will create a way to continuously identify future generations of vaccines.

Panacea Biotech is the third largest biotechnology company (according to ABE survey, 2011), as well as 50 top pharmaceuticals.